Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Net Cash Flow: 2019-2024

Historic Net Cash Flow for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $10.3 million.

  • Kymera Therapeutics' Net Cash Flow fell 617.79% to -$222.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 92.46%. This contributed to the annual value of $10.3 million for FY2024, which is 75.10% down from last year.
  • Kymera Therapeutics' Net Cash Flow amounted to $10.3 million in FY2024, which was down 75.10% from $41.3 million recorded in FY2023.
  • Over the past 5 years, Kymera Therapeutics' Net Cash Flow peaked at $41.3 million during FY2023, and registered a low of -$45.2 million during FY2020.
  • Moreover, its 3-year median value for Net Cash Flow was $20.4 million (2022), whereas its average is $24.0 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Net Cash Flow plummeted by 224.40% in 2020, and later soared by 147.57% in 2021.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Net Cash Flow stood at -$45.2 million in 2020, then skyrocketed by 147.57% to $21.5 million in 2021, then decreased by 4.96% to $20.4 million in 2022, then surged by 101.89% to $41.3 million in 2023, then slumped by 75.10% to $10.3 million in 2024.